Boston Life Sciences Appoints Frank Bobe as Executive Vice President and Chief Business Officer
April 16 2007 - 10:00AM
PR Newswire (US)
Veteran Pharmaceutical Executive Will Lead BLSI's Business
Development Efforts HOPKINTON, Mass., April 16
/PRNewswire-FirstCall/ -- Boston Life Sciences, Inc.,
(NASDAQ:BLSI), a biopharmaceutical company focused on the research
and clinical development of diagnostic and therapeutic products for
central nervous system (CNS) disorders, announced today the
appointment of Frank Bobe, Ph.D. as Executive Vice President and
Chief Business Officer. Dr. Bobe will be responsible for managing
and expanding the Company's commercial and corporate development
activities. "Frank joins Boston Life Sciences during a very
exciting period as we transition our company's focus to the
development of therapeutic solutions for nerve repair," said Chief
Executive Officer Peter Savas. "Frank's proven track record in
cultivating and structuring research and development partnerships
and identifying new business opportunities, combined with his broad
commercial experience, will add to the depth and breadth of our
executive team as we seek to expand and mature our development
pipeline." Dr. Bobe has over 20 years of biotechnology and
pharmaceutical industry experience. He joins Boston Life Sciences
from BioAxone Therapeutic, Inc. of Canada, where he served as
President and Chief Executive Officer since March 2005. In addition
to initiating BioAxone's clinical trial of Cethrin in acute spinal
cord injury, Dr. Bobe was responsible for guiding BioAxone's
corporate strategy, developing its operating plan, and advancing
its technical development platforms. Dr. Bobe played a key role in
BioAxone's licensing of Cethrin and related intellectual property
and technology to Boston Life Sciences for nerve repair therapies
following debilitating injuries to the spinal cord. Prior to
joining BioAxone, Dr. Bobe was Chief Executive Officer and Country
Head of the South Korean affiliate of Novartis AG, where he
successfully launched several brands, implemented alliances with
local and global partners and built a new management team. Prior to
joining Novartis Korea, Dr. Bobe held operational management and
global corporate leadership positions at Novartis AG, with
increasing responsibilities in preclinical research, sales and
marketing and general management. Dr. Bobe holds a Ph.D. in
Bio-organic Chemistry from the University of California at Davis
and completed a postdoctoral research fellowship in biochemistry in
the laboratory of Nobel Laureate Prof. Bruce Merrifield,
Rockefeller University, New York. Dr. Bobe also holds an MBA from
INSEAD in Fontainebleau, France. About Boston Life Sciences Boston
Life Sciences, Inc. (BLSI) is engaged in the research and clinical
development of diagnostic and therapeutic products for central
nervous system (CNS) disorders. Cethrin(R), a
recombinant-protein-based drug designed to promote nerve repair
after acute spinal cord injury, has reported positive interim
results in a Phase I/IIa clinical trial. ALTROPANE(R), a molecular
imaging agent is in Phase III clinical trials for the diagnosis of
Parkinson's Disease (PD). The Company's research and pre-clinical
CNS programs include Inosine for the treatment of spinal cord
injury and stroke, a DAT blocker for the treatment of Parkinson's
disease, and a second generation technetium-based molecular imaging
agent for PD and ADHD. BLSI's current research collaborations
include Harvard Medical School and Children's Hospital Boston. Safe
Harbor The foregoing release contains certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward- looking statements include statements
regarding Boston Life Sciences' future expectations, beliefs,
intentions, goals, strategies, plans or prospects regarding the
future, including the Company's licensing arrangement with
BioAxone, including the development and commercialization of
Cethrin, the prospects of the Company's CNS therapeutics program,
the Company's strategies to develop and commercialize axon
regeneration technologies and the breadth of the Company's
technologies and intellectual property portfolio. Forward- looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "estimate,"
"expect," "intend," "is planned," "may," "should," "will," "will
enable," "would be expected," "look forward," "may provide,"
"would" or similar terms, variations of such terms or the negative
of those terms. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors including those
risks, uncertainties and factors referred to in the Company's
Annual Report on Form 10-K for the year ended December 31, 2006
filed with the Securities and Exchange Commission under the section
"Risk Factors," as well as other documents that may be filed by
Boston Life Sciences from time to time with the Securities and
Exchange Commission. As a result of such risks, uncertainties and
factors, the Company's actual results may differ materially from
any future results, performance or achievements discussed in or
implied by the forward-looking statements contained herein. Boston
Life Sciences is providing the information in this press release as
of this date and assumes no obligations to update the information
in this press release. Contact: Sharon Correia Boston Life
Sciences, Inc. +1-508-497-2360 ext. 224 DATASOURCE: Boston Life
Sciences, Inc. CONTACT: Sharon Correia of Boston Life Sciences,
Inc., +1-508-497-2360 ext. 224,
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024